{ "abstract": "Background: Anti-integrin αvβ6 immunoglobulin G autoantibodies have emerged as one of the most accurate non-invasive biomarkers for ulcerative colitis (UC). We aimed to validate their diagnostic performance in a French multicentre cohort of patients with inflammatory bowel disease (IBD) and to evaluate their predictive value for vedolizumab clinical response.\n\nMethods: We performed a multicentre, non-interventional post hoc analysis using prospectively collected serum samples and clinical data from two parent prospective observational studies: VEDOPREDIRESP (patients with IBD initiating vedolizumab) and GOLILOR (patients with UC undergoing golimumab dose intensification). Serum anti-αvβ6 autoantibody titres were quantified by ELISA at baseline and week 6 (VEDOPREDIRESP) or week 8 (GOLILOR), blinded to clinical outcomes. The primary endpoint was sustained clinical remission at week 52.\n\nResults: In the VEDOPREDIRESP cohort (n=115; 67 UC, 48 Crohn’s disease (CD), sustained clinical remission at week 52 was achieved in 54% of patients with UC. Baseline serum anti-αvβ6 autoantibody titres were significantly higher in UC than in CD (median 271 ng/mL (IQR 38–884) vs 5.2 ng/mL (2.5–10), p<0.001), with seropositivity (>9.1 ng/mL) in 94% vs 19%, respectively. Receiver operating characteristic (ROC) analysis confirmed excellent diagnostic performance to discriminate between UC and CD (area under the ROC curve (AUC) 0.93; optimal cut-off 15 ng/mL; sensitivity 92%, specificity 95%). In patients with UC treated with vedolizumab, titres declined significantly from baseline to week 6 (median 243 ng/mL (176–884) to 190 ng/mL (89–320), p=0.040). A >30% reduction at week 6 strongly predicted sustained remission at week 52 (AUC 0.79; sensitivity 78%, specificity 80%). Multivariable analysis identified this early decline as the only statistically significant independent predictor of 1-year remission (adjusted OR 5.36, 95% CI 1.12 to 8.54, p=0.040). Notably, in an independent cohort of 47 patients with UC undergoing golimumab dose intensification, there was no reduction in median serum anti-αvβ6 autoantibody levels, with levels remaining stable from 197 ng/mL at week 0 to 205 ng/mL (97–457) at week 8 (p=0.730).\n\nConclusions: Anti-αvβ6 autoantibodies robustly discriminate UC from CD. In patients with UC treated with vedolizumab, their early and selective decline predicts clinical remission at 1 year and provides a precision tool to optimise gut-selective therapy in real time.", "abstract_shown": true, "affiliations": [ "Department of Gastroenterology, University Hospital of Saint-Étienne, Saint-Étienne, France", "CIRI (Centre International de Recherche en Infectiologie), Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Étienne, Saint-Étienne, France", "Department of Immunology, Saint-Étienne University, Saint-Étienne, France", "Department of Immunology, iBio Thera Reference Center, University Hospital of Saint-Étienne, Saint-Étienne, France", "Department of Gastroenterology, Amiens University Hospital, Amiens, France", "Department of Gastroenterology, Lyon-Sud Hospital, Lyon, France", "Department of Gastroenterology and Clinical Nutrition, CHU Nice, Nice, France", "Department of Gastroenterology, Hôpitaux Universitaires Bicêtre, Paris, France", "Centre for Epidemiology and Population Health (CESP), INSERM, Paris, France", "Department of Hepato-Gastroenterology, CHU Montpellier, Montpellier, France", "Department of Gastroenterology, Monash University, Clayton, Victoria, Australia", "CIC 1408, University Hospital of Saint-Étienne, Saint-Étienne, France" ], "article_type": "research article", "arxiv": null, "author_total": 12, "authors": [ { "affs": [ 0, 1 ], "name": "Xavier Roblin" }, { "affs": [ 2 ], "name": "Fatma Mechi" }, { "affs": [ 1, 3 ], "name": "Anne-Emmanuelle Berger" }, { "affs": [ 4 ], "name": "Mathurin Fumery", "orcid": "0000-0002-2337-2902" }, { "affs": [ 1, 5 ], "name": "Stéphane Nancey" }, { "affs": [ 6 ], "name": "Xavier Hébuterne" }, { "affs": [ 7, 8 ], "name": "Franck Carbonnel" }, { "affs": [ 9 ], "name": "Romain Altwegg" }, { "affs": [ 0 ], "name": "Mathilde Barrau" }, { "affs": [ 10 ], "name": "Miles P Sparrow" }, { "affs": [ 0 ], "name": "Gerard Duru" }, { "affs": [ 1, 3, 11 ], "name": "Stephane Paul", "orcid": "0000-0002-8830-4273" } ], "bibtex": "https://research.draconitic.com/paper/fgtaa8vjn52y6.bib", "cited_by": 0, "doi": "10.1136/egastro-2026-100598", "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13735267/", "id": "fgtaa8vjn52y6", "issns": [ "2766-0125", "2976-7296" ], "landing_url": "https://doi.org/10.1136/egastro-2026-100598", "language": "en", "licence": "CC-BY-NC-4.0", "licence_label": "CC BY-NC 4.0", "licence_source": "article", "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/", "metadata_licence": null, "native_subjects": [ [ "heading", "1506" ], [ "heading", "Original Research" ], [ "openalex", "2715|Inflammatory Bowel Disease" ] ], "openalex": "W7225090140", "pdf_url": null, "pmcid": "PMC13735267", "pmid": "42991140", "published": "2026-11-02", "publisher": "BMJ Publishing Group", "ris": "https://research.draconitic.com/paper/fgtaa8vjn52y6.ris", "sources": [ { "first_seen": "2026-11-09T12:20:58Z", "native_id": "PMC13735267", "source": "pmc", "url": "https://doi.org/10.1136/egastro-2026-100598" } ], "subjects": [ { "field": "medicine", "origin": "openalex:2715|Inflammatory Bowel Disease", "subfield": "general" } ], "title": "Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis", "title_text": "Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis", "type": "peer-reviewed", "updated_at": "2026-11-09T12:20:58Z", "url": "https://research.draconitic.com/paper/fgtaa8vjn52y6", "venue": "eGastroenterology", "versions": [] }